J01XX08 - Linezolid |
Propably not porphyrinogenic |
PNP |
Rationale
Linezolid is not metabolised by CYP450 enzymes.
Risk for gastrointestinal adverse events in the form of nausea, vomiting and diarrhoea motivates vigilance against insufficient intake of food, especially of carbohydrate.
Chemical description
Linezolid is a member of the antibiotic group oxazolidinones.
Therapeutic characteristics
Common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are diarrhoea, vomiting and nausea.
Metabolism and pharmakokinetics
Linezolid is a member of the antibiotic group oxazolidinones.
Linezolid is not detectably metabolised by CYP450 enzymes and does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 (SPC).
Linezolid demonstrated no response in an hPXR transactivation assay (Sinz 2006).
References
- Scientific articles
- Sinz M, Kim S, et al. Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab. 2006 May;7(4):375-88. PMID 16724927. #4323
- Summary of Product Characteristics
- Norwegian medicines agency. Summary of Product Characteristics (SPC). Linezolid. #1662
Similar drugs
© NAPOS 2024